Fibrotech Therapeutics Pty Ltd

Boehringer Ingelheim International Gmbh

Richard Ernest Gilbert

Darren James Kelly

David Stapleton

Steven Zammit

Henry Krum

Thomas Klein

Spencer John Williams

Andrew Advani

Kim Alexander Connelly

Spencer John Willams

Substituted cinnamoyl anthranilate compounds exhibiting anti-fibrotic activity; or derivatives thereof, analogs thereof, pharmaceutically acceptable salts thereof, and metabolites thereof, with the proviso that the compound is no Tranilast.

Therapeutic compounds

The present invention relates to the use of 1-[(4-methyl-quinazolin-2-yl)methyl]-3 -methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine for use in a patient being at risk of or having heart failure with preserved ejection fraction (HFpEF).

Medical use of a DPP-4 inhibitor

Substituted cinnamoyl anthranilate compounds exhibiting anti-fibrotic activity; or derivatives thereof, analogues thereof, pharmaceutically acceptable salts thereof, and metabolites thereof; with the proviso that the compound is not Tranilast.

Growing community of inventors

Toronto, Canada

Richard Ernest Gilbert